SeraCare Life Sciences Inc

SeraCare Life Sciences — Investor Presentation (June 2008)

22 slides from SeraCare Life Sciences's investor presentation, Jun 25, 2008

  1. Slide 1: SeraCare Life Sciences

    SeraCare Life Sciences NASDAQ: SRLS June 25, 2008

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this presentation are forward

  3. Slide 3: SeraCare: Products and Services for the Life Sciences Industry

    SeraCare: Products and Services for the Life Sciences Industry SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, validation and production of human diagnostics and therapeutics.

  4. Slide 4: Key Events

    Key Events March 06 Stock delisted; Bankruptcy filing Summer 06 Sue Vogt & Greg Gould hired May 07 Emerged from bankruptcy New BOD $20M rights offering June 07 $10M line of credit Sold less profitable lines of business; reengineered sales team; focused on product development Sept 2007 $23.7M NIH con

  5. Slide 5: Today and Looking Forward

    SeraCare Today and Looking Forward Best-in-class reputation for quality products and services First class customer base Attractive market opportunities In vitro diagnostics Biotechnology and pharmaceutical Evolution of personalized medicine Near-term goal of double-digit revenue growth Strategy for

  6. Slide 6: Customer Universe

    SeraCare Customer Universe Drug & Vaccine Research, Development, Manufacturing pissTeenees + human and bovine serum albumin lood Testing ‘* PBMCs, ELISpot, chromogens + controls and panels + serology and NAT + eQuality software suite Research & : Clinical Trials In vitro Diagnostic Research, Develop

  7. Slide 7: Some of Our Valued Customers

    Some of Our Valued Customers Pharmaceutical and Biotechnology In Vitro Diagnostics Manufacturers Diagnostics Government Agencies Laboratories, Blood Banks, Proficiency

  8. Slide 8: Global Sales & Distribution

    Global Sales & Distribution 14 sales representatives in U.S. Distributors in 6 countries 2 sales representatives (Germany and Spain) Distributors in 19 countries Distributors in 7 countries Distributors in 2 countries Americas Europe Pacific Rim Middle East / Africa

  9. Slide 9: SeraCare Business Segments

    PRODUCTS SERVICES SeraCare Business Segments Manufacturing & Research Products Quality Control Products Biobanking & Research Services

  10. Slide 10: Quality Control Products

    Quality Control Products ~60% to 70% of all medical decisions involve a diagnostic test Vertically integrated consumer base across growing diagnostics market Diagnostic controls used to verify integrity of test results Reference labs Hospital labs Blood banks IVD manufacturing

  11. Slide 11: Quality Control Products: ACCURUN Controls

    SeraCare Quality Control Products ACCURUN(r) Controls Quality control and validation panels Comprehensive selection of infectious disease markers, both serology and nucleic acid testing (NAT) ACCURUN eQuality Integrated Quality Control Software Suite Projected launch Q109

  12. Slide 12: Manufacturing and Research Products

    Manufacturing and Research Products Products used in the discovery, development and manufacturing of diagnostics, therapeutics and vaccines Explosive growth in biomarker discovery 50%+ growth in new clinical trials Dramatically increasing funding for vaccine research and development Broad applicatio

  13. Slide 13: Manufacturing and Research Products

    SeraCare Manufacturing and Research Products Human processed plasma Cell culture supplements Plasma-derived excipients Seroconversion panels Characterized disease state plasma Cellular immunology products Cultured viruses

  14. Slide 14: Biobanking and Research Services Markets

    Biobanking and Research Services Markets Clinical trials and research support services Clinical specimen management Testing services National Cancer Institute initiative to increase quality of biospecimens Increased emphasis on risk management makes biobanks critical partners in product development

  15. Slide 15: Biobanking

    SeraCare Biobanking Managing/storing over 18 million biological samples for government and commercial customers Over 80,000 square feet dedicated to repository operations SeraCare has the best-in-class biorepository

  16. Slide 16: Research Services

    SeraCare Research Services Clinical trial support, viral culture and molecular services Contract research services in molecular biology, virology and immunology Custom BioServices provide support for many segments of the life science industry

  17. Slide 17: Market Trends Converge: Era of Personalized Medicine

    Market Trends Converge: Era of Personalized Medicine Identify new disease-related biomarkers Stratify patient populations for specific therapies Make better, safer medication choices Insure appropriate dosing options Facilitate more focused, faster clinical trials Optimize utilization to decrease ov

  18. Slide 18: The SeraCare/Customer Value Chain: Case Study

    The SeraCare/Customer Value Chain: Case Study Discovery Development Manufacturing Clinical Use SRLS provides Performance Panels to aid in test development SRLS develops positive controls to validate test results SRLS becomes approved supplier of reagents used in manufacturing of kit SRLS supplies ex

  19. Slide 19: Management Team

    Management Team Susan L.N. Vogt, President & Chief Executive Officer Millipore Corporation Gregory A. Gould, Chief Financial Officer Integrated BioPharma, Atrix Laboratories, Colorado MEDtech Ronald R. Dilling, Vice President, Operations Celliance, Hazelton Biologics (JRH BioSciences) Kathryn E. She

  20. Slide 20: Financials - 2Q08, Ending 3/31/08

    Financials - 2Q08, Ending 3/31/08 Revenue $12.5 million vs. $14.0 million Q207 Gross margins $4.7M (38% of revenue) Operating loss $0.2M vs. $3.8M Q207 Net loss $0.3M ($0.02 per share) vs $3.9M ($0.27) Q207 Cash and equivalents $6.0 million Total assets $61.6 million 18.6 million shares outstanding

  21. Slide 21: Corporate Growth Strategy

    Corporate Growth Strategy Focus on core segments - molecular diagnostics, vaccine development and cellular assays Increased sales coverage Expanded distribution channels Introduction of new products Controls for genetic testing Cellular products for immune response monitoring Expand business ex-US C

  22. Slide 22: SeraCare Life Sciences

    SeraCare Life Sciences NASDAQ: SRLS June 25, 2008

SeraCare Life Sciences — Investor Presentation (June 2008) on 6ix